Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 20131 AL 20145

Third degree heart block following intramuscular ziprasidone

Tambyraja R, Strawn JR.

Schizophr Res. 2011 Feb;125(2-3):302-3. doi: 10.1016/j.schres.2010.07.015. Epub 2010 Aug 7.

Technology-aided verbal instructions to help persons with mild or moderate Alzheimer's disease perform daily activities

Lancioni GE, Singh NN, O'Reilly MF, Sigafoos J, Tatulli E, Rigante V, Zonno N, Perilli V, Pinto K, Minervini MG.

Res Dev Disabil. 2010 Nov-Dec;31(6):1240-50. doi: 10.1016/j.ridd.2010.07.021. Epub 2010 Aug 8.

Sharpen that needle

Herskovits AZ, Growdon JH.

Arch Neurol. 2010 Aug;67(8):918-20. doi: 10.1001/archneurol.2010.151.

Alzheimer's disease-the inexorable epidemic

Lee TS, Krishnan KR.

Ann Acad Med Singap. 2010 Jul;39(7):505-2.

Cognitive intervention in Alzheimer disease

Buschert V, Bokde AL, Hampel H.

Nat Rev Neurol. 2010 Sep;6(9):508-17. doi: 10.1038/nrneurol.2010.113. Epub 2010 Aug 17.

[Decision making in the elderly: which tools for its evaluation by the clinician?]

Hommet C, Constans T, Atanasova B, Mondon K.

Psychol Neuropsychiatr Vieil. 2010 Sep;8(3):201-7. doi: 10.1684/pnv.2010.0221.

Why are drug trials in Alzheimer's disease failing?

Lancet. 2010 Aug 28;376(9742):658. doi: 10.1016/S0140-6736(10)61316-5.

(99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease

Devanand DP, Van Heertum RL, Kegeles LS, Liu X, Jin ZH, Pradhaban G, Rusinek H, Pratap M, Pelton GH, Prohovnik I, Stern Y, Mann JJ, Parsey R.

Am J Geriatr Psychiatry. 2010 Nov;18(11):959-72. doi: 10.1097/JGP.0b013e3181ec8696.

Amyloid imaging: coming to a PET scanner near you

Jagust WJ.

Ann Neurol. 2010 Sep;68(3):277-8. doi: 10.1002/ana.22144.

Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report

Na HR, Kim S, Choi SH, Yang DW, Bae HJ, Kim JE, Park MY, Shim YS, Kim BK, Kwon JC, Yoo BG, Kim BC, Lee JS.

Geriatr Gerontol Int. 2011 Jan;11(1):90-7. doi: 10.1111/j.1447-0594.2010.00649.x. Epub 2010 Sep 3.

Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial

Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSh, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi A.

J Clin Pharm Ther. 2010 Oct;35(5):581-8. doi: 10.1111/j.1365-2710.2009.01133.x.

EFNS guidelines for the diagnosis and management of Alzheimer's disease

Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P; EFNS Scientist Panel on Dementia.

Eur J Neurol. 2010 Oct;17(10):1236-48. doi: 10.1111/j.1468-1331.2010.03040.x.

Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes

Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S.

Arch Neurol. 2011 Jan;68(1):51-7. doi: 10.1001/archneurol.2010.225. Epub 2010 Sep 13.

A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease

Geldmacher DS, Fritsch T, McClendon MJ, Landreth G.

Arch Neurol. 2011 Jan;68(1):45-50. doi: 10.1001/archneurol.2010.229. Epub 2010 Sep 13.

Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy

Olazarán J, Reisberg B, Clare L, Cruz I, Peña-Casanova J, Del Ser T, Woods B, Beck C, Auer S, Lai C, Spector A, Fazio S, Bond J, Kivipelto M, Brodaty H, Rojo JM, Collins H, Teri L, Mittelman M, Orrell M, Feldman HH, Muñiz R.

Dement Geriatr Cogn Disord. 2010;30(2):161-78. doi: 10.1159/000316119. Epub 2010 Sep 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias